Aveo Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for AVEO PHARMS, and when can generic versions of AVEO PHARMS drugs launch?
AVEO PHARMS has one approved drug.
There are three US patents protecting AVEO PHARMS drugs.
There are fifty-two patent family members on AVEO PHARMS drugs in twenty-six countries and eleven supplementary protection certificates in ten countries.
Summary for Aveo Pharms
| International Patents: | 52 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Aveo Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aveo Pharms | FOTIVDA | tivozanib hydrochloride | CAPSULE;ORAL | 212904-002 | Mar 10, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Aveo Pharms | FOTIVDA | tivozanib hydrochloride | CAPSULE;ORAL | 212904-001 | Mar 10, 2021 | RX | Yes | No | 6,821,987 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Aveo Pharms | FOTIVDA | tivozanib hydrochloride | CAPSULE;ORAL | 212904-002 | Mar 10, 2021 | RX | Yes | Yes | 6,821,987 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Aveo Pharms | FOTIVDA | tivozanib hydrochloride | CAPSULE;ORAL | 212904-001 | Mar 10, 2021 | RX | Yes | No | 7,166,722 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Aveo Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 1273466 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2020097106 | ⤷ Try a Trial |
| Japan | 2004224800 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2004035572 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Aveo Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1382604 | 600 | Finland | ⤷ Try a Trial | |
| 1382604 | C201830013 | Spain | ⤷ Try a Trial | PRODUCT NAME: TIVOZANIB O UNA SAL O SOLVATO DEL MISMO, EN PARTICULAR, EL HIDROCLORURO MONOHIDRATO; NATIONAL AUTHORISATION NUMBER: EU/1/17/1215; DATE OF AUTHORISATION: 20170824; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1215; DATE OF FIRST AUTHORISATION IN EEA: 20170824 |
| 1382604 | 18C1006 | France | ⤷ Try a Trial | PRODUCT NAME: TIVOZANIB OU UN DE SES SELS OU DE SES SOLVATES,EN PARTICULIER LE CHLORHYDRATE MONOHYDATE; REGISTRATION NO/DATE: EU/1/17/1215 20170829 |
| 1559715 | 2018/009 | Ireland | ⤷ Try a Trial | PRODUCT NAME: TIVOZANIB OR A SALT OR SOLVATE THEREOF, IN PARTICULAR, THE HYDROCHLORIDE MONOHYDRATE; REGISTRATION NO/DATE: EU/1/17/1215 20170829 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
